share_log

MVAP Medical Supplies Submits Major Order for NeuroCaps, Sees Huge Opportunity in Pediatrics

MVAP Medical Supplies Submits Major Order for NeuroCaps, Sees Huge Opportunity in Pediatrics

MVAP 医疗用品提交了 NeuroCaps 的重大订单,看到了儿科的巨大机遇
GlobeNewswire ·  2023/02/16 10:20

NeuroCapTM is the right combination of performance and ease of use for better patient care – especially for pediatric neurodiagnostic applications

NeuroCTM 是性能和易用性的正确组合,可改善患者护理,尤其适用于儿科神经诊断应用

LAKEWOOD RANCH, Fla., Feb. 16, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Brain Scientific (OTCQB:BRSFD), a Florida-based applied science technology company, announces today that it has received a major order for NeuroCaps from MVAP Medical Supplies.

佛罗里达州莱克伍德牧场,2023年2月16日(GLOBE NEWSWIRE)——通过InvestorWire——总部位于佛罗里达州的应用科学技术公司Brain Scientific(OTCQB: BRSFD)今天宣布,它已收到MVAP Medical Supplies的NeuroCaps大订单。

"Brain Scientific has got it right," said Eric Jensen, CEO of MVAP Medical Supplies, Inc. "Their NeuroCap is the product our customers have been waiting for. Its ease of use and simplicity coupled with high performance and quality make it a winner to us."

“Brain Scientific做对了,” MVAP Medical Supplies, Inc.首席执行官埃里克·詹森说,“他们的NeuroCap是我们的客户一直在等待的产品。它的易用性和简单性以及高性能和质量使它成为我们的赢家。”

MVAP Medical Supplies, an industry leader in the sleep, EEG, EMG, IOM, respiratory and patient care supplies space, will help Brain Scientific further expand its sales and distribution network to key growth markets as Brain Scientific continues to position itself as the leader in the quickly emerging medical wearables space.

随着Brain Scientific继续将自己定位为快速崛起的医疗可穿戴设备领域的领导者,睡眠、脑电图、肌电图、IOM、呼吸和患者护理用品领域的行业领导者MVAP Medical Supplies将帮助Brain Scientific进一步将其销售和分销网络扩展到关键增长市场。

"We always knew that our NeuroCap was a game changer for neurology, especially when it comes to putting children through an EEG test," said Hassan Kotob, CEO of Brain Scientific. "We're thrilled to see the market embracing our solution and look forward to a great partnership with MVAP Medical Supplies."

Brain Scientific首席执行官哈桑·科托布说:“我们一直都知道我们的NeuroCap改变了神经病学的游戏规则,尤其是在让孩子接受脑电图测试方面。”“我们很高兴看到市场接受我们的解决方案,并期待与MVAP Medical Supplies建立良好的合作伙伴关系。”

About Brain Scientific

关于《大脑科学》

Brain Scientific Inc. (brainscientific.com) is an applied sciences technology company with multiple patents and FDA-cleared products. Brain Scientific is committed to developing next-gen solutions that advance the future of medical and OEM devices. Brain Scientific has two product lines covering neurology and precision motion. The NeuroCap™ and NeuroEEG™ are smart neurological diagnostic devices that simplify administration, shorten scan time and cut costs. The Piezo Motion product line consists of ultra-efficient compact precision motors that will drive the next generation of OEM devices. To learn more about Brain Scientific's corporate strategy, products or investor relations, please visit brainscientific.com.

Brain Scientific Inc.(brainscientific.com)是一家应用科学技术公司,拥有多项专利和美国食品药品管理局批准的产品。Brain Scientific致力于开发下一代解决方案,推动医疗和OEM设备的未来。Brain Scientific有两条产品线,涵盖神经病学和精准运动。NeuroCap™ 和 NeuroEEG™ 是智能神经系统诊断设备,可简化管理、缩短扫描时间并降低成本。Piezo Motion 产品线由超高效的紧凑型精密电机组成,将驱动下一代 OEM 设备。要了解有关Brain Scientific的企业战略、产品或投资者关系的更多信息,请访问brainscientific.com。

Forward-Looking Statements

前瞻性陈述

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of EEG products and services and piezo motor technology; (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items; (iii) the company's future financial performance; (iv) the successful integration of Piezo Motion with and into Brain Scientific; and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, over many of which the company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the company's inability to obtain additional financing; the significant length of time and resources associated with the development of products and related insufficient cash flows and resulting illiquidity; the company's inability to expand its business; significant government regulation of medical devices and the healthcare industry; lack of product diversification; volatility in the price of the company's raw materials; and failure to implement the company's business plans or strategies. Some of these and other factors are identified and described in more detail in the company's filings with the SEC. The company does not undertake to update these forward-looking statements.

本新闻稿中包含的任何未描述历史事实的陈述都可能构成前瞻性陈述。前瞻性陈述可能包括但不限于关于 (i) 管理层未来运营的计划和目标的陈述,包括与脑电产品和服务以及压电电机技术的设计、开发和商业化有关的计划或目标;(ii) 收入(包括收益/亏损)、每股收益(包括收益/亏损)、资本支出、股息、资本结构或其他财务项目的预测;(iii)公司未来的财务业绩;(iii)iv) Piezo Motion 成功与并输入 Brain Scientific;以及 (v) 上述第 (i)、(iii) 或 (iv) 点中描述的任何陈述所依据或与之相关的假设。此类前瞻性陈述并不旨在预测或保证实际业绩、业绩、事件或情况,可能无法实现,因为它们基于公司当前的预测、计划、目标、信念、预期、估计和假设,并受许多风险和不确定性以及其他影响的影响,其中许多是公司无法控制的。由于这些风险和不确定性,某些事件和情况的实际结果和时间可能与前瞻性陈述所描述的结果存在重大差异。可能影响或促成前瞻性陈述不准确或导致实际业绩与预期或预期业绩存在重大差异的因素可能包括但不限于公司无法获得额外融资;与产品开发相关的时间和资源过长以及相关的现金流不足以及由此产生的流动性不足;公司无法扩展业务;政府对医疗器械和医疗保健行业的严格监管;缺乏产品多元化;公司原材料价格的波动;以及未能实施公司的业务计划或战略。该公司向美国证券交易委员会提交的文件中对其中一些因素和其他因素进行了更详细的识别和描述。公司不承诺更新这些前瞻性陈述。

CONTACTS

联系人

INVESTORS
ir@brainscientific.com

投资者们
ir@brainscientific.com

MEDIA
pr@brainscientific.com

媒体
pr@brainscientific.com

Corporate Communications

企业传播

IBN (InvestorBrandNetwork)
Los Angeles, California
310.299.1717 Office
Editor@InvestorBrandNetwork.com

IBN(投资者品牌网络)
加利福尼亚州洛杉矶
310.299.1717 办公室
Editor@InvestorBrandNetwork.com


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发